Pathstone Family Office’s Medifast MED Stock Holding History

Pathstone Family Office’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,283	Closed	-$247K	–	1368
2022 Q3	$247K	Sell	2,283 -1,965	-46%	-$282K	﹤0.01%	1012
2022 Q2	$767K	Buy	4,248 +2,248	+112%	+$402K	0.02%	418
2022 Q1	$371K	Buy	+2,000	New	+$377K	0.01%	667
2019 Q3	–	Sell	-101	Closed	-$13K	–	680
2019 Q2	$13K	Sell	101 -238	-70%	-$33.1K	﹤0.01%	491
2019 Q1	$43K	Hold	339	–	–	0.01%	324
2018 Q4	$43K	Buy	+339	New	+$58K	0.01%	199

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Pathstone Family Office's MED Position: Q4 2022 in Review

Pathstone Family Office sold out of Medifast (MED) in Q4 2022, closing a stake of 2,283 shares — an estimated $247K sold.

Pathstone Family Office first reported a position in MED in Q4 2018 and held it in 6 quarters. The position peaked at $767K in Q2 2022. 277 funds tracked by Wall St. Rank hold MED as of Q4 2022.

Pathstone Family Office reported no remaining Medifast position as of Q4 2022 after selling out during the quarter.
Pathstone Family Office sold 2,283 Medifast shares in Q4 2022, an estimated $247K.
Pathstone Family Office first reported a position in Medifast in Q4 2018 and held it in 6 quarters.
Pathstone Family Office's Medifast position peaked at $767K in Q2 2022.
277 funds tracked by Wall St. Rank held Medifast as of Q4 2022.

Based on Pathstone Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.